ASH 2022 | The emerging role of menin inhibitors in the treatment of NPM1-mutated and KMT2A-rearranged R/R AML
Amir Fathi
• 6 Dec 2022
Amir Fathi, MD, MPH, Massachusetts General Hospital, Boston, MA, comments on the promise of menin inhibition in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) with NPM1 mutations or KMT2A alterations. This interview took place at the 64th ASH Annual Meeting and Exposition Congress held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy – Genentech, BMS/Celgene, Foghorn, Kite, Morphosys, Abbvie, Takeda, Ipsen, Forma, Amgen, Novartis, Astellas, Immunogen, Mablytics, EnClear, Orum, PureTech, Daiichi Sankyo, Pfizer Research funding – BMS/Celgene, Abbvie, Agios/Servier
